hVIVO plc Director's Dealings (3086D)
October 08 2018 - 9:00AM
UK Regulatory
TIDMHVO
RNS Number : 3086D
hVIVO plc
08 October 2018
hVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
London, UK, 8 October 2018: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, announces
that application has been made to AIM for the admission of 6,420
new ordinary shares of 5.0p each in the Company (the "New Ordinary
Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jim Winschel (Non-Executive Director) of new ordinary
shares, under the terms of his letter of appointment as set out in
the Company's announcement of 4 November 2014 which stated that Mr
Winschel had entered into a binding commitment to purchase GBP4,000
of hVIVO plc new ordinary shares per quarter.
The New Ordinary Shares represent Mr Winschel's investment for
the quarter ended 30 September 2018. On 8 October 2018, Mr Winschel
invested in an additional 6,420 ordinary shares, at a price of 62.3
pence per share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 80,581,494 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 12 October 2018. Following
Admission, Mr Winschel will be interested in a total of 79,558
ordinary shares of 5.0p in the Company, representing 0.1% of the
Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
a) Name Jim Winschel
--------------------------- --------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/ Non-Executive Director
status
--------------------------- --------------------------------------------
b) Initial notification/ Initial Notification
Amendment
--------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name hVIVO plc
--------------------------- --------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the financial
instrument,
type of instrument GB00B6ZM0X53
Identification
code
--------------------------- --------------------------------------------
b) Nature of Acquisition of ordinary shares
the transaction
--------------------------- --------------------------------------------
c) Currency GBP
--------------------------- --------------------------------------------
d) Price(s) and Director Price (p) Volume
volume(s) Jim Winschel 62.3 6,420
---------- -------
---------------------------
e) Aggregated
information
- Aggregated
volume
- Price 6,420
- Aggregated 62.3p
total
GBP3,999.66
--------------------------- --------------------------------------------
f) Date of the 8 October 2018
transaction
--------------------------- --------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------- --------------------------------------------
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (Director, Investor Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial
platform to accelerate drug and vaccine development in respiratory
and infectious diseases. Leveraging human disease models in flu,
RSV, HRV and respiratory indications, the hVIVO platform captures
disease in motion, illuminating the entire disease life cycle from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted more than 50 clinical studies and inoculated
over 2500 volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUGGPAUUPRGGR
(END) Dow Jones Newswires
October 08, 2018 09:00 ET (13:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024